FTC (Federal Trade Commission) probes DaVita/Gambro Healthcare deal further
This article was originally published in Clinica
The US Federal Trade Commission (FTC) has requested additional information from DaVita and Gambro regarding the former's planned $3.05bn acquisition of the latter's Gambro Healthcare US dialysis services business. A spokesperson for Stockholm, Sweden-based Gambro told Clinica: "We believe that any antitrust issues can be overcome." She added that the deal was a very good one for both parties.